For immediate release

Seinäjoki, Finland, November 4, 2022

Election of the Members of the Board of Directors

The Annual General Meeting resolved, for the time until the end of the next Annual General Meeting, to re-elect Per Benjaminsen and Oskar Wegelius and elect Terry Virts, Dr. Diane E. Clayton, and Anders Eriksson as Members of the Board of Directors. Terry Virts was elected as the Chairman of the Board of Directors. Marin Bjørklund and Patricia Wicklund were not re-elected, and the Company thanks them for their service.

Remuneration to the Board of Directors

The Annual General Meeting resolved that the Chairman shall receive remuneration of EUR 2,000 in cash and EUR 20,000 paid in shares and that every other Board Member shall receive remuneration of EUR 2,000 in cash and EUR 10,000 paid in shares. Further, the Board is offered option rights during the two months following the EGM, from November 5, 2024, until January 4, 2024, free of charge. Each option right will entitle its holder to subscribe for one new share in the Company. The share subscription period begins on July 1, 2025, and ends on September 30, 2025. The subscription price will be SEK 0,60. The option rights allocated to the Board of Directors are 100,000 to each ordinary member of the Board and 200,000 to the Chairman of the Board.

Confirmation of the remaining authorization to the Board of Directors to decide on the issuance of shares, options, and other special rights

The Extraordinary General Meeting resolved to re-authorize the Board of Directors to decide, in one or more transactions, on the issuance of up to a total of 38,658,289 shares and the issuance of options and other special rights entitling to shares referred to in Chapter 10 Section 1 of the Companies Act. The Board of Directors decides on all other terms and conditions of issuing shares, options, and other special rights entitled to shares. If there is a weighty financial reason for the Company, the issuance of shares, options, and other special rights entitling to shares may be carried out in deviation from the shareholders' pre-emptive rights (directed issue). The authorization is valid until June 30, 2025.

For more information, please contact:

Stein Ulve, CEO

Email: stein@eeviahealth.com

Phone: +358400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares at the Spotlight Stock Market in Sweden under the short name EEVIA (https://spotlightstockmarket.com/en/companies/irabout?InstrumentId=XSAT000085FD).

To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn @EeviaHealth.